Back to the main directory
Company Analysis / Equity
- Q4 Results, On-Track To
Commence Enrollment by Zacks
- Revenue Slumps But Not Expected To Be Long-Term Trend by Zacks
- SMLR: Another Revenue Record, Installed Base Jumps, Wellchec Looks Promising by Zacks
- SMLR: Firing On All Cylinders as WellChec & Instruments Remain On A Tear by Zacks
- SMLR: Record Quarter. WellChec Reorg Prompts Upward Revision to Price Target by Zacks
- SMLR: Revenue Jumps 44% YOY, 14% Sequentially. Maintaining Buy Rec by Zacks
- SMLR: Solid Q4 With Revenue Up 35% by Zacks
- SNWV: 100% Wound Closure @ 20 Weeks. FDA Approval One Step Closer! by Zacks
- SNWV: DMC Recommendation Causes At Least 4 Month Delay by Zacks
- SNWV: FDA Filing Expected in June/July by Zacks
- SNWV: Int l Sales Picking Up, FDA Meeting Q1 2016 by Zacks
- SNWV: Management Guiding For FDA Response in January by Zacks
- SNWV: Mixed 24-Week Data, Will Discuss At Upcoming FDA Meeting by Zacks
- SNWV: Positive Feedback From FDA, Forging Ahead With PMA by Zacks
- SNWV: Q4 Results. Updated FDA Plan by Zacks
- SNWV: Switch To De Novo Makes Sense by Zacks
- Trial Enrollment Off To Strong Start by Zacks
- Sales expected to grow further in 2013; valuation very attractive---Outperform. by Zacks
- Second Quarter Financials Disappointing, But Outlook Optimistic For 2H11 by Zacks
- Second quarter sales resumed growth, but immediate financing is needed by Zacks
- PURE: Total revenue increased 77% for the fiscal year, gross margin increased to 66% from previous 61% by Zacks
- AKTS: Continued Performance Improvement Spurs Increasing Customer Interest by Zacks
- Q1 Results In-Line. by Zacks
- Recent Sell-Off Unwarranted. Moving to Outperform by Zacks
- STLT: Advancing Snake-Venom Based Cancer Fighting Agents by Zacks